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everse Epidemiology of
onventional Cardiovascular Risk
actors in Patients With Chronic Heart Failure
amyar Kalantar-Zadeh, MD, MPH,*† Gladys Block, PHD,† Tamara Horwich, MD,‡
regg C. Fonarow, MD, FACC‡
orrance, Berkeley, and Los Angeles, California
Traditional risk factors of a poor clinical outcome and mortality in the general population,
including body mass index (BMI), serum cholesterol, and blood pressure (BP), are also found
to relate to outcome in patients with chronic heart failure (CHF), but in an opposite
direction. Obesity, hypercholesterolemia, and high values of BP have been demonstrated to
be associated with greater survival among CHF patients. These findings are in contrast to the
well-known associations of over-nutrition, hypercholesterolemia, and hypertension with a
poor outcome in the general population. The association between traditional cardiovascular
risk factors and an adverse clinical outcome in CHF patients is referred to as “reverse
epidemiology.” The mechanisms for this inverse association in CHF is not clear. There are
other populations with a similar risk factor reversal phenomenon, including patients with
end-stage renal disease receiving dialysis, those with advanced malignancies, and individuals
with advanced age. Several possible causes are hypothesized: the time discrepancy of the
competing risk factors may play a role; the presence of the “malnutrition-inflammation
complex syndrome” in CHF patients may explain the existence of reverse epidemiology; and
a decreased level of lipoprotein molecules may distort their endotoxin-scavenging role,
predisposing CHF patients with a low serum cholesterol level to inflammatory consequences
of endotoxemia. It is possible that new goals for such traditional risk factors as BMI, serum
cholesterol, and BP should be developed for CHF. Reverse epidemiology of conventional
cardiovascular risk factors is observed in CHF and may have a bearing on the management
of these patients; thus, it deserves further investigation. (J Am Coll Cardiol 2004;43:
1439–44) © 2004 by the American College of Cardiology Foundationl
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thronic heart failure (CHF) is a progressive disease that
esults in substantial morbidity and mortality (1,2). The
onventional cardiovascular risk factors (i.e., obesity, hyper-
holesterolemia, hypertension) are associated with an inde-
endently increased risk of developing CHF and mortality
n the general population (3). Numerous recent reports
ndicate that in marked contrast to the general population,
here these cardiovascular risk factors are associated with
ncreased risk of an adverse outcome, a higher body mass
ndex (BMI), increased serum cholesterol concentration,
nd higher blood pressure (BP) values are strongly corre-
ated with decreased morbidity and mortality in CHF
atients (Table 1) (4–6). These paradoxical observations,
hich have also been reported in patients with end-stage
enal disease (ESRD) undergoing dialysis treatment, have
een referred to as “reverse epidemiology” (7). These studies
all into question the practice of extrapolating cardiovascular
isk factor targets or goals derived from the general popu-
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ward.
Manuscript received September 7, 2003; revised manuscript received October 30,w003, accepted November 4, 2003.ation to the CHF population without separate study. The
henomenon of an established risk factor in the general
opulation having a markedly different and indeed opposite
redictive pattern may not be unique to the CHF or ESRD
opulations. Elderly individuals in nursing homes (8),
ospitalized patients (9), patients with malignancy (10), and
ossibly other subpopulations may have similar reverse
pidemiology. Hence, a better understanding of the causes
f reverse epidemiology in CHF may help refine the
reatment goals and result in an improved outcome in this
nd other similar but distinct populations.
eight and BMI: is obesity favorable? Epidemiologic
tudies have shown a strong relationship between obesity
nd increased risk of cardiovascular disease and mortality in
he general population (11–13). In some studies of normal
dults, a “J” or “U” curve effect has been observed, in which
hose individuals with a low BMI also demonstrated in-
reased mortality, although not as high as that in obese
ndividuals (12,13).
Increased BMI is associated with an increased risk of
eart failure (3,14). However, patients with more severe
HF tend to have lower BMI values than do age- and
ender-matched control subjects from the general popula-
ion (15–17). A study of prognostic variables in 401 patients
ith CHF did not find overweight status to be a risk factor
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Reverse Epidemiology in CHF April 21, 2004:1439–44or mortality, despite inclusion of 40% overweight pa-
ients with BMI 26 kg/m2 (18). In the Systolic Hyper-
ension in the Elderly Program study, overweight status was
ssociated with a decreased stroke risk and reduced total
ortality, as compared with lean subjects with CHF (19).
orwich et al. (5) studied 1,203 individuals with moderate
o severe CHF (60% in New York Heart Association
NYHA] functional class IV). A higher BMI was associated
ith a better two-year survival rate. One- and five-year
urvival showed the same trend, although the association
as not statistically significant. Multivariate analysis showed
n inverse association between BMI and mortality (Fig. 1).
In the Rotterdam Study cohort (20), both cardiac death
nd all-cause mortality were lower in obese CHF patients.
avos et al. (21) examined the impact of BMI in 589
atients with CHF who did not have cachexia. On multi-
ariate analyses, a higher BMI (as a continuous variable)
onferred better survival (21). Lissin et al. (22) reported a
imilar finding in 522 veteran patients with CHF, in that
atients with BMI 22 kg/m2 had worse survival and those
ith BMI 30 kg/m2 had the best survival. Finally, Lavie
t al. (23) also reported the obesity paradox, in that a better
vent-free survival was observed with higher body-
omposition quintiles in 209 consecutive ambulatory pa-
ients with NYHA functional class I to III heart failure. In
his study, the BMI and percent body fat associated with an
dverse outcome were at levels generally considered to be
healthy,” and not at levels consistent with a cachectic state
23). It should be noted that this so-called “obesity paradox”
s not restricted to CHF but is indeed a well-described
Abbreviations and Acronyms
BMI  body mass index
BP  blood pressure
CHF  chronic heart failure
ESRD  end-stage renal disease
MICS  malnutrition–inflammation complex syndrome
NYHA  New York Heart Association
PEM  protein-energy malnutrition
TNF  tumor necrosis factor
able 1. Reverse Epidemiology of Cardiovascular Risk Factors in
Risk Factors of
Cardiovascular
Disease
Direction of the Associations Betw
Risk Factors and Outcomes
General Population CHF
MI High BMI and obesity are
deleterious (13).
High BMI and ob
(5,19–23,37).
erum cholesterol Hypercholesterolemia, high
LDL cholesterol, and
low HDL cholesterol are
deleterious (25).
Hypercholesterole
high LDL chol
protective (6,22
P Hypertension is deleterious
(37).
A low systolic BP
poor outcome (MI  body mass index; BP  blood pressure; CHF  chronic heart failure; HDL  hhenomenon in several other distinct populations, including
SRD patients undergoing dialysis (7,24) and elderly indi-
iduals (8).
erum cholesterol: is hypercholesterolemia desirable?
lthough hypercholesterolemia is a well-defined risk factor
or morbidity and mortality in the general population (25),
he relationship between cholesterol and clinical outcome in
atients with CHF does not appear to be conventional.
redevoe et al. (26) reported that low total cholesterol,
ow-density lipoprotein cholesterol, high-density lipopro-
ein cholesterol, and triglyceride concentrations related to
mpaired survival in 109 CHF patients. In another study by
ichartz et al. (27), the perioperative mortality of 45
atients with severe CHF supported by a left ventricular
ssist device was significantly associated with hypocholes-
erolemia, whereas hypercholesterolemia was protective.
auchhaus et al. (28) found that low total serum cholesterol
evels (200 mg/dl) were predictive of impaired 12-month
vent-free survival in 51 patients with CHF, independent of
he cause of CHF (ischemic or nonischemic) and the
resence of cachexia. The largest epidemiologic study in this
egard was conducted by Horwich et al. (6), in that among
onic Heart Failure
Commentsnts
are protective Increased BMI is a risk factor for CHF development
(3,14). Elderly, smoking, maintenance dialysis,
and hospitalized patients have an inverse
association similar to CHF patients (7).
and maybe
lemia) is
8).
There may be similar associations between low
cholesterol and mortality in elderly or smoking
persons and dialysis or AIDS patients
(7,29,30,36).
indicates
8–41).
Similar reverse associations between BP and outcome
have been described in dialysis patients (43).
igure 1. Risk-adjusted survival curves for the four body mass index (BMI)
ategories at five years. Survival was significantly better for the overweight
nd obese BMI categories. (From Horwich et al. [5], with permission.)Chr
een
Patie
esity
mia (
estero
,26–2
often
1,20,3igh-density lipoprotein; LDL  low-density lipoprotein.
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April 21, 2004:1439–44 Reverse Epidemiology in CHF,134 patients with advanced CHF, those with a low total
holesterol level had a significantly lower albumin level, left
entricular ejection fraction, and cardiac output. Total,
ow-density lipoprotein, and high-density lipoprotein cho-
esterol and triglycerides each predicted survival significantly
p  0.01) on univariate analysis, with improved survival at
igher levels (Fig. 2). After adjustment for risk factors using
Cox proportional hazards models, relative risks were 2.07,
.37, 1.39, and 1.01 for the first, second, third, and fourth
otal cholesterol quintiles, respectively, as compared with
he fifth (highest) quintile (6). The cohort study by Lissin et
l. (22) showed that surviving patients with CHF had a
igher prevalence of hyperlipidemia than did deceased
atients.
Similar findings regarding the association of low serum
holesterol and poor outcome have been reported for elderly
ndividuals (29–32). Volpato et al. (30,31) found that
mong 4,128 elderly patients with a mean age of 79 years,
he all-cause mortality was significantly higher in those with
low serum cholesterol level, defined as 160 mg/dl, as
ompared with those with normal or high serum cholesterol
oncentrations. Similar to patients with CHF, hypocholes-
erolemia has been shown to be associated with adverse
utcomes in ESRD patients undergoing dialysis (33), cancer
atients (34), and individuals with AIDS (35).
lood pressure: are lower blood pressure values
eleterious? The role of hypertension as a risk factor for
ncreased cardiovascular or cerebrovascular events in the
eneral population is indisputable (36). However, elevated
P may not represent the primary risk for overall survival in
HF patients; several studies have failed to show that high
P is an independent mortality risk factor in CHF patients
20,37–39). Ghali et al. (37) showed that in 78 patients with
ecompensated CHF, both systolic and diastolic BP levels
ere lower in the deceased patients compared with survi-
ors. In another cohort of 102 patients with CHF who
nderwent echocardiography, Rihal et al. (38) showed that
igher systolic BP was independently predictive of subse-
uent survival. Cowie et al. (39) demonstrated that in 220
atients with incident CHF, higher systolic BP was inde-
igure 2. Five-year rates of death or urgent heart transplantation by deciles
f total cholesterol. (From Horwich et al. [5], with permission.)endently predictive of improved cardiovascular survival. aimilarly, in the Rotterdam Study, a higher BP level
onferred a more favorable prognosis among 181 subjects
ith CHF (20). In a large cohort of outpatients consecu-
ively enrolled in the Registry of Italian Network on CHF
1), higher systolic BP was among very few independent
redictors of survival in 1,033 elderly patients (age 70
ears) with CHF. In the study by Muntwyler et al. (40) of
11 CHF patients (NYHA functional class II to IV), one of
he statistically significant (p 0.05) predictors of mortality
as lower systolic BP (relative risk 2.4). Recently, Poole-
ilson et al. (41) conducted a randomized, double-blinded
tudy of 3,164 patients with CHF and showed that higher
ystolic BP at baseline was independently associated with a
tatistically significant lower mortality rate. Similar to pa-
ients with CHF, in dialysis-maintained patients, a reverse
ssociation has been reported between BP and mortality
42).
ossible explanations for reverse epidemiology. The
oncept of reverse epidemiology appears at first to be
ystifying, especially because obesity, increased levels of
erum cholesterol, and high BP values are such well-
stablished risk factors for ischemic heart disease and CHF
n the general population. The paradox becomes even more
aramount when it is recognized that it is not a question of
he existence or lack of an association between these risk
actors and clinical outcomes, but often the complete
eversal and indeed the opposite direction of this relation-
hip. Hence, there must be prevailing conditions that are
haracteristically present in CHF patients, which render
hem more susceptible to a poor outcome when low body
ass, low BP, or decreased serum values of serum choles-
erol are present. Alternately, once CHF develops, these
actors may actually provide patients with protection against
HF disease progression. Several suggested explanations
re offered as possible mechanisms for this inverse
ssociation.
ime discrepancies among competitive risk factors.
urvival advantages that exist in obese and hypercholester-
lemic CHF patients with high BP values may, in the short
erm, outweigh the harmful effects of these risk factors on
ardiovascular disease in the long term. Because CHF
atients have a mortality risk that is substantially greater
han that in the general population (1), the long-term effects
f these risk factors on future mortality may be over-
helmed by the short-term effects of other factors on CHF
ortality. In the U.S. general population, as well as in most
ndustrialized countries, manifestations of over-nutrition,
uch as obesity and hypercholesterolemia, are major risk
actors for cardiovascular mortality (25,43). These are also
ountries where people have a greater life expectancy, as
ompared with individuals in other parts of the world. In
ontrast, in developing countries, undernutrition is still a
owerful determinant of a poor clinical outcome and mor-
idity and mortality, leading to a shorter life expectancy
44). Thus, in CHF patients who have a short life expect-
ncy, any factor that may improve short-term survival, such
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Reverse Epidemiology in CHF April 21, 2004:1439–44s obesity or hypercholesterolemia, may exert a desirable
ffect on longevity, whereas conditions that are traditionally
ssociated with long-term survival may not be relevant.
alnutrition–inflammation complex syndrome (MICS).
ardiac cachexia has been identified as an independent risk
actor for mortality in CHF (17). Twenty-four percent of
HF patients have hypoalbuminemia (3.5 mg/dl) and
8% have muscle atrophy (15). In advanced CHF, cachexia
nd wasting appear to be independent predictors of in-
reased mortality (45). An important feature of cardiac
achexia is related to the inflammatory syndrome (16).
umor necrosis factor (TNF)-alpha has been reported to be
ignificantly increased in patients with CHF cachexia (46),
s in the cases of cachectic patients with a variety of cancers,
nfections, or vascular diseases (47). Anker et al. (48) found
hat TNF-alpha was twofold higher in cachectic CHF
atients than in non-cachectic control subjects. This chronic
nflammatory state may have resulted from bacterial or
ndotoxin translocation due to bowel wall edema after
evere heart failure (49). The inflammatory response may be
esponsible for the wasting syndrome and hypoalbuminemia
n CHF (50). It has been postulated that the common link
etween CHF and cachexia is inflammation (51). The
echanism for the development of protein-energy malnu-
rition (PEM) in CHF patients may be cytokine activation
ssociated with increased endotoxin absorption or reduced
learance, especially in the setting of hypolipoproteinemia.
n the other hand, PEM and inflammation may each
ndependently contribute to hypoalbuminemia, cachexia,
nd subsequently increased morbidity and mortality in
HF. However, as both PEM and inflammation are
trongly associated with each other and can change many
utritional measures in the same direction, and because the
elative contributions of measures of these two conditions to
ach other and to outcomes in CHF patients are not yet well
efined, we propose to use the term MICS, which has also
een suggested for a similar condition in dialysis patients
52).
The existence of paradoxical risk factors could be accen-
uated by MICS, possibly in several ways. First, patients
ho are underweight or who have low serum cholesterol
ay be suffering from MICS and its poor outcome (51).
econd, the aforementioned paradoxical factors may indi-
ate a state of undernutrition, which may predispose to
nfection or other inflammatory processes (53). Finally,
hen individuals are malnourished, they are more suscep-
ible to the ravages of inflammatory diseases (54). Hence,
ny condition that potentially attenuates the magnitude of
EM or inflammation should be favorable to CHF patients.
significant association between low diastolic BP, low
MI, and risk of death in a cohort of CHF patients has
een shown (22). In dialysis patients, the association be-
ween low BP and an adverse outcome may also reflect a
reater systemic inflammatory response in such patients
54). Hence, the association between lower BP and a worse putcome may account for the lower BP association with
ICS in CHF patients.
ndotoxin-lipoprotein hypothesis. Lower serum total
holesterol and lipoprotein concentrations are strongly and
ndependently associated with impaired survival in CHF
atients (55). Increases in lipopolysaccharide levels have
een shown in CHF patients as compared with the general
opulation (53,55). Higher concentrations of total choles-
erol may reflect a richer pool of internal lipoproteins that
an actively bind to and remove circulating entotoxins, thus
emoving their deleterious effect in causing inflammation
nd subsequent atherosclerosis in CHF patients (53).
lasma concentrations of lipopolysaccharides are raised in
dematous patients with CHF who also show substantial
mmune activation and inflammation (53). The finding of
igher lipopolysaccharide concentrations in patients with
evere CHF (53), as well as abnormal monocyte responsive-
ess to lipopolysaccharides (56), makes it a strong possibility
hat mononuclear cells contribute to the generation of
nflammatory cytokines in CHF. Rauchhaus et al. (28,55)
ave hypothesized that there is an optimal lipoprotein
oncentration below which a lipid reduction would be
etrimental due to inadequate lipopolysaccharide binding.
urvival bias. Because CHF patients have undergone spe-
ific processes of selection and survival, their characteristics
ay not be similar to those of the general population.
ccording to an analysis based on the National Health and
utrition Examination Survey (57), in the U.S., there are
ver 50 million patients with cardiac or vascular disease who
re at increased risk of developing CHF. However, the
umber of people with clinically evident CHF is approxi-
ately five million. A higher proportion of patients with
eart disease and conventional risk factors do not reach the
HF stage due to their higher mortality, as compared with
hose with heart disease lacking these risk factors. Hence,
hose who manage to survive to reach CHF despite con-
entional risk factors may have other protective factors that
therwise negate the adverse effects of the conventional risk
actors. Whatever the survival features are, these “unfortu-
ately lucky” individuals may be considered as “specifically
elected” patients who are not necessarily genetically or
henotypically similar to their predecessors and may not
ave the survival characteristics and epidemiologic features
f their progenitors. Hence, a survival bias, which is a form
f selection bias, may heavily influence the epidemiologic
onstellations in this smaller proportion of cardiovascular
urvivors (i.e., CHF patients).
everse causation. The direction of a causal pathway may
e reversed in the paradoxical associations described in
HF patients. Hence, it may not be normotension or
ypotension, per se, that is detrimental, but rather the
nderlying cause of low BP (i.e., cardiac pump failure). This
henomenon, known as “reverse causation” (58), indicates
hat low BP, BMI, or serum cholesterol values are not
tiologically linked to a higher mortality rate in CHF
atients; they are merely markers of a poor outcome.
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April 21, 2004:1439–44 Reverse Epidemiology in CHFowever, even if these associations are devoid of causation
r have a reversed direction, the counterfactual inference
mplies that maneuvers that would avoid hypotension or
eight loss in CHF patients may be beneficial in their
urvival.
linical implications. Why were these striking findings
egarding an inverse association between conventional car-
iovascular risk factors and mortality in CHF only recently
eported, and should they be believed? A publication bias
ay have handicapped or delayed reporting such paradox-
cal findings in CHF patients, as the investigators’ first
mpression upon encountering results with an inversed
ssociation may be to consider them erroneous (59). As
ore reports indicative of reverse epidemiology in CHF
ave been published recently, more investigators appear to
ave been encouraged to report their “reverse” findings. The
oncept of CHF being a systemic inflammatory disease is
elatively recent and may have provided biologic plausibility
o the seemingly paradoxical associations.
Although the term “reverse epidemiology” may be a
isnomer, we advocate the use of this nomenclature, not
nly because it is stimulating but also because this phenom-
non has been clearly described in dialysis patients under the
ame terminology. The etiology of reverse epidemiology in
HF patients may be quite different for various risk factors.
n other words, factors that lead to a positive association
etween obesity and better survival in these patients may be
ifferent from those leading to the association between
ower BP and mortality. Nevertheless, it is important to first
xhaust the possibility of one single unifying entity to
ccount for all or most of the aforementioned risk factor
eversals. We believe that MICS is the best candidate.
evertheless, we have offered several additional plausible
ypotheses.
We believe that in CHF patients, more attention should
e focused on optimal management of undernutrition and
nflammation, based on possible mechanisms responsible for
he reverse epidemiology. However, premature conclusions
o lower doses or discontinue antihypertensive or anti-
yperlipidemic treatment should be avoided until such
nformation is forthcoming. The antihypertensive drugs,
eurohormonal antagonists, angiotensin-converting enzyme
nhibitors, and beta-blockers clearly prolong life in CHF
atients, irrespective of their hemodynamic effects and the
xistence of reverse epidemiology for BP and outcome. The
ntihypercholesterolemic agent, hydroxymethylglutaryl co-
nzyme A reductase inhibitor (a statin), may have an
nti-inflammatory effect that can be beneficial in the man-
gement of the elements of MICS and improved outcome
n CHF patients, irrespective of cholesterol-lowering effects
60). A recent study by Horwich et al. (61) has shown an
ndependent association of statin use and lower mortality in
atients with ischemic and nonischemic heart failure.
Although the data presented in this review suggest that a
igher BMI, higher BP, and hypercholesterolemia are
ssociated with reduced morbidity and mortality in theulnerable population with CHF, it is possible that, in the
ong run, CHF patients with these risk factors may suffer
rom more cardiovascular consequences if they survived for
sufficiently longer period of observation. As more effective
reatments for CHF patients become available, it is possible
hat there may be a “reversal of the reverse epidemiology”
nd a return to traditional epidemiology for many subgroups
f CHF patients, as currently found in heart transplant
atients (62). The question may remain unanswered as to
hat is indeed the normal epidemiology and what is reverse.
dentification of the mechanisms for the reversal of the
raditional associations will be most beneficial to the im-
roving our understanding of the pathophysiology of CHF
nd improving the care of these patients.
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